医学
观察研究
加压素
优势比
置信区间
感染性休克
药物治疗
重症监护医学
荟萃分析
内科学
肾脏替代疗法
败血症
标识
DOI:10.1177/10600280221096881
摘要
In this month’s Annals of Pharmacotherapy, the largest observational study assessing the early versus later use of vasopressin has been published. When this new study is combined with the other available observational studies, there are 2 important outcomes to focus on. When all the observational studies are pooled together, no reduction in new onset arrhythmias is seen (odds ratio [OR] = 0.91, 95% confidence interval [CI] = 0.41-1.95) with early versus late vasopressin use while the reduction in renal replacement therapy just missed statistical significance (OR = 0.56, 95% CI = 0.32-1.00). Early vasopressin likely does not reduce new onset arrhythmias versus later use but might reduce the need for renal replacement therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI